More importantly, iRhom1 shows negative correlation with prognosis in those patient cohorts with chemotherapy treatment in both triple negative breast cancer (TNBC) and CRC (Fig. 1a), suggesting a likely role of iRhom1 in chemosensitivity. This evidence concerns the gene RHBDF1 and triple-negative breast carcinoma.